
PNEUMONIA PART II

DR UMMAR KHURSHID



RECURRENT PNEUMONIA

Recurrent Pneumonia

≥2 episodes of pneumonia within 6 months

or

≥3 episodes in a lifetime

Episodes separated by an asymptomatic interval of at least 1 month

or

Radiographic clearing of densities between episodes

Causes of Recurrent Pneumonia

- **Bronchial obstruction (bronchial carcinoma, adenoma, foreign body)**
- **Lung disease (Bronchial asthma, bronchiectasis, lung abscess, cystic fibrosis, sequester segment of lung—commonly left lower lobe)**
- **Aspiration (achalasia cardia, scleroderma, pharyngeal pouch)**
- **Immunocompromised patient (HIV, DM, lymphoma, leukemia, multiple myeloma)**



Discharge

Discharge and follow-up

- **Depends on their home circumstances and the likelihood of complications.**
- **A chest x-ray need not be repeated before discharge in those making a satisfactory clinical recovery.**
- **Clinical review should be arranged around 6 weeks later**
- **A chest x-ray obtained if there are persistent symptoms, physical signs or reasons to suspect underlying malignancy.**

Criteria for discharge

To discharge, the patient should be clinically stable with no more than one of the following clinical signs:

- **Temperature > 37.8 °C**
- **Heart rate > 100/min**
- **Respiratory rate > 24/min**
- **Systolic BP < 90 mm Hg**
- **SaO₂ < 90%**
- **Inability to maintain oral intake**
- **Abnormal mental status.**

Remember

Before Discharge!!!!

- Influenza Vaccine
- Pneumococcal Vaccine

After Discharge!!!

- Follow up CXR to exclude cancer



Prevention

Preventive measures

- **Current smokers should be advised to stop smoking**
- **Influenza Vaccine & Pneumococcal Vaccine should be considered in selected pts**
- **In developing countries, tackling malnutrition & Indoor air pollution**
- **Immunization against measles, pertussis & Haemophilus influenzae type b in children**
- **Legionella pneumophila has important public health implications and usually requires notification to the appropriate health authority.**



COMPLICATIONS

Complication of pneumonia

- **Para-pneumonic effusion – common**
- **Empyema**
- **Retention of sputum causing lobar collapse**
- **Deep vein thrombosis and pulmonary embolism**
- **Pneumothorax, particularly with *Staph. aureus***
- **Suppurative pneumonia/lung abscess**
- **ARDS, renal failure, multi-organ failure**
- **Pleurisy**

Complication of pneumonia...

- **Hypoxemia**
- **Atelectasis**
- **Respiratory failure (which requires mechanical ventilator)**
- **Sepsis, which may lead to organ failure**
- **Ectopic abscess formation (*Staph. aureus*)**
- **Hepatitis, pericarditis, myocarditis, meningoencephalitis**
- **Pyrexia due to drug hypersensitivity**



Vaccination

Influenza and pneumococcal vaccines in old age

- **Influenza vaccine reduces the risk of influenza and death in elderly people.**
- **Polysaccharide pneumococcal vaccines do not appear to reduce the incidence of pneumonia or death but may reduce the incidence of invasive pneumococcal disease.**

(Andrew R, et al(Cochrane Review). Cochrane Library, issue 4, 2003. Oxford: Update software.)



Prognosis

-
-
- **Most patients respond promptly to antibiotic therapy and will improve within 2 weeks**
 - **Elderly or very sick patients may need longer treatment**
 - **However, fever may persist for several days and the chest X-ray often takes several weeks or even months to resolve, especially in old age.**
 - **The mortality rate of adults with non-severe pneumonia is very low (< 1%); hospital death rates are typically between 5 and 10% but may be as high as 50% in severe illness.**



HAP (Hospital Acquired Pneumonia)

HAP (Hospital-acquired pneumonia)

- **Hospital-acquired or nosocomial pneumonia is a new episode of pneumonia occurring at least 2 days after admission to hospital.**
- **New episode of pneumonia occurring at least 48 h post admission to hospital, excludes infection incubating at time of admission (Am J Respir Crit Care Med 153:1711-25, 1995).**
- **Second most common hospital-acquired infection.**
- **leading cause of HAI-associated death.**

HCAP & VAP

□ Healthcare-associated pneumonia (HCAP):

Development of pneumonia in a person who has spent at least 2 days in hospital within the last 90 days,

- **Has attended a haemodialysis unit**
- **Received intravenous antibiotics, or home infusion therapy**
- **Resident in a nursing home or other long-term care facility**
- **Home wound care**
- **Family member with multidrug-resistant pathogen**

□ Ventilator-associated pneumonia(VAP):

The elderly are particularly at risk, along with patients in intensive care units, especially when mechanically ventilated; in the latter case, the term 'ventilator-associated pneumonia' (VAP) is used.

HAP (Hospital-acquired pneumonia)..

- **Early-onset HAP** (occurring within 4–5 days of admission) are similar to those involved in CAP.
- **Late onset HAP** is associated with a different range of pathogens to CAP

The organisms

- Gram-negative bacteria (e.g. **Escherichia, Pseudomonas, Klebsiella species and Acinetobacter baumannii**),
- **Staph. aureus** (including the **meticillin resistant type (MRSA)**)
- anaerobes.

Factors predisposing to hospital-acquired pneumonia

Aspiration of nasopharyngeal or gastric secretions

- **Immobility or reduced conscious level**
- **Vomiting, dysphasia (NB. stroke disease), achalasia or severe reflux**
- **Nasogastric intubation**

Bacteria introduced into lower respiratory tract

- **Endotracheal intubation/ tracheostomy**
- **Infected ventilators/nebulisers/bronchoscopes**
- **Dental or sinus infection**

Factors predisposing to hospital-acquired pneumonia...

Reduced host defenses against bacteria

- **Reduced immune defenses (e.g. corticosteroid treatment, diabetes, malignancy)**
- **Reduced cough reflex (e.g. post-operative)**
- **Disordered mucociliary clearance (e.g. anaesthetic agents)**
- **Bulbar or vocal cord palsy**

Bacteraemia

- **Abdominal Sepsis,**
- **IV Cannula Infection,**
- **Infected Emboli**

Factors predisposing to hospital-acquired pneumonia...

- **Chronic lung disease (COPD, bronchiectasis)**
- **Frequent suction**
- **Other serious illness such as heart disease, liver cirrhosis, and DM**
- **Recent cold, laryngitis or flu**
- **Immuno-suppressed patients**
- **Difficult swallowing (due to stroke, dementia, parkinsons disease, or other neurological conditions)**
- **Impaired consciousness (loss of brain function due to dementia, stroke, or other neurological conditions)**

Clinical features

The diagnosis should be considered in any hospitalized or ventilated patient who develops

- **Purulent sputum (or endotracheal secretions),**
- **New radiological infiltrates,**
- **An otherwise unexplained increase in oxygen requirement,**
- **A core temperature of more than 38.3°C, and**
- **A leucocytosis or leucopenia.**

Management

In early-onset HAP

➤ **Patients who have received no previous antibiotics can be treated with**

- **Co-amoxiclav or Cefuroxime.**

➤ **If the patient has received a course of recent antibiotics, then**

- **Piperacillin / Tazobactam or**
- **a third generation Cephalosporin should be considered**

Management..

In late-onset HAP

the choice of antibiotics must cover the

- **Gram-negative bacteria,**
- **Staph. aureus (including MRSA) and**
- **anaerobes.**

Antipseudomonal cover may be provided by a

- **carbapenem (meropenem) or**
- **a third-generation cephalosporin combined with an aminoglycoside.**

Management..

- **MRSA cover may be provided by**
 - **glycopeptides, such as Vancomycin or Linezolid**
- **Physiotherapy is important to aid expectoration in**
 - **the immobile and**
 - **elderly**
- **nutritional support is often required.**

Antimicrobial options for common infecting bacteria

Organism	Antimicrobial options
Staph. aureus	Flucloxacillin, Clindamycin
Pseudomonas aeruginosa	Ciprofloxacin, Piperacillin-tazobactam, Aztreonam, Meropenem, Aminoglycosides, Ceftazidime/Cefepime
Enterobacter spp.	Ciprofloxacin, Meropenem, Aminoglycosides
Anti microbial option for MRSA	Clindamycin, Vancomycin, Rifampicin (Never used as monotherapy), Linezolid, Daptomycin, Tetracyclines, Tigecycline, Co-trimoxazole.

Prevention: HAP

Despite appropriate management, **the mortality from HAP is approximately 30%**, so prevention is very important.

- **Good hygiene is paramount, particularly with**
 - **handwashing**
 - **equipment used**
- **To minimise the chances of aspiration**
- **To limit use of stress ulcer prophylaxis with PPI**
- **Oral antiseptic/mouth wash**

Prevention: HAP...

- **The risk of aspiration should be minimized**
- **Oral antiseptic (chlorhexidine 2%) be used to may decontaminate the upper airway,**
- **Some intensive care units employ selective decontamination of the digestive tract when the anticipated requirement for ventilation will exceed 48 hours.**

Prevention: HAP...

- **Frequent turning of bed** **patients** **and**
ridden ambulation as much as **early**
possible
- **Coughing and breathing techniques**
- **Sterilization of respiratory therapy equipment**
- **Suctioning of secretion in the unconscious** **who have**
poor cough and swallowing reflexes, to prevent aspiration
of secretions and its accumulation

Prevention: HAP...

- **To prevent aspiration during nasogastric tube feedings**
- **check the position of tube and administer feedings slowly**
- **To control the spread of infection, dispose secretions properly.**

Prevention: HAP...

➤ **Vaccination**

Influenza & Pneumococcus

- **Isolation of patients with resistant respiratory tract infections**
- **Enteral nutrition**
- **Choice of GI prophylaxis**
- **Subglottic secretion removal**

HAP – Failure of Therapy

- **Incorrect diagnosis (it is not pneumonia): Atelectasis, CHF, PE with infarction, lung contusion, chemical pneumonitis, ARDS, pulmonary hemorrhage**
- **Pathogen resistance**
- **Host factors that increase mortality**
 - **Age > 60, prior pneumonia, chronic lung disease**
 - **immunosuppression**
- **Antibiotic resistance**



Respiratory Infection In Old Age

Respiratory infection in old age

□ **Increased risk of and from respiratory infection: because of reduced immune responses, increased closing volumes, reduced respiratory muscle strength and endurance, altered mucus layer, poor nutritional status and the increased prevalence of chronic lung disease.**

□ **Predisposing factors: other medical conditions may predispose to infection. e.g. swallowing difficulties due to stroke increase the risk of aspiration pneumonia.**

Respiratory infection in old age...

- **Atypical presentation:** Older patients often present with confusion, rather than breathlessness or cough.
- **Mortality:** The vast majority of deaths from pneumonia in developed countries occur in older people.
- **Influenza:**
 - **Higher complication rate, morbidity and mortality.**
 - **Vaccination significantly reduces morbidity and mortality in old age but uptake is poor.**

Respiratory infection in old age...

□ Tuberculosis:

- **Most TB cases in old age represent reactivation of previous, often unrecognized disease**
- **Precipitated by steroid therapy, diabetes mellitus and the factors above.**
- **Cryptic miliary TB is an occasional alternative presentation.**
- **Older people more commonly suffer adverse effects from antituberculous chemotherapy and require close monitoring.**



HAP – Risk Factors

Risk Factors For Multidrug-resistant Pathogens Causing HAP,HCAP,VAP

- **Antimicrobial therapy in preceding 90 days**
- **Current hospitalization of 5 days or more**
- **High frequency of antibiotic resistance in the community or
in the specific hospital unit**
- **Immunosuppressive disease and/or therapy**

HAP – Modifying Factors

Penicillin-resistant and drug-resistant pneumococci

- **Age > 65 yr**
- **B-Lactam therapy within the past 3 months**
- **Alcoholism**
- **Immune-suppressive illness (including therapy w/ corticosteroids)**
- **Multiple medical comorbidities**
- **Exposure to a child in a day care center**

HAP – Modifying Factors

Enteric gram-negatives

- **Residence in a nursing home**
- **Underlying cardiopulmonary disease**
- **Multiple medical comorbidities**
- **Recent antibiotic therapy**

HAP – Modifying Factors

Pseudomonas aeruginosa

- **Structural lung disease (bronchiectasis)**
- **Corticosteroid therapy (10 mg of prednisone per day)**
- **Broad-spectrum antibiotic therapy for > 7 d in the past month**
- **Malnutrition**

Pneumonia: Risk Factors

CAP

- **Older adult**
- **Chronic/coexisting condition**
- **Recent history or exposure to viral or influenza infections**
- **History of tobacco or alcohol use**

HAP

- **Older adult**
- **Chronic lung disease**
- **Aspiration**
- **ET, Trach, NG / GT**
- **Immunocompromised**
- **Mechanical ventilation**



Pneumonia In The Immunocompromised Patient

Pneumonia in the immunocompromised patient...

- **Patients immunocompromised by drugs or disease (particularly HIV) are at high risk of pulmonary infection.**
- **The majority of cases are caused by the same pathogens that cause pneumonia in non-immunocompromised individuals.**
- **Patients with more profound immunosuppressant, unusual organisms or those normally considered to be of low virulence or non-pathogenic may become 'opportunistic' pathogens.**

Pneumonia in the immunocompromised patient...

Patients with more profound immunosuppression, unusual organisms or those normally considered to be of low virulence or non-pathogenic may become 'opportunistic' pathogens. Infection is often due to more than one organism.

- **Gram-negative bacteria, especially *Pseudomonas aeruginosa*,**
- **viral agents,**
- **fungi,**
- **mycobacteria, and**
- **less common organisms such as *Nocardia asteroides* has to be considered.**

Causes of immune suppression-associated lung infection

Defective Phagocytic function	
Causes	Infecting organisms
Acute leukaemia	Gram-positive bacteria including Staph. aureus
Cytotoxic drugs	
Agranulocytosis	Gram-negative bacteria
	Fungi, e.g. Candida albicans, Aspergillus fumigatus

Causes of immune suppression-associated lung infection...

Defects in cell-mediated immunity	
Causes	Infecting organisms
Immunosuppressive drugs Cytotoxic chemotherapy Lymphoma Thymic aplasia	Viruses Cytomegalovirus ,Herpesvirus, Adenovirus ,Influenza Fungi Pneumocystis jirovecii (formerly carinii) Candida albicans Aspergillus fumigatus

Causes of immune suppression-associated lung infection...

Defects in antibody production	
Causes	Infecting organisms
Multiple myeloma	Haemophilus influenzae
Chronic lymphocytic leukaemia	Mycoplasma pneumoniae

Clinical features of Pneumonia in the immunocompromised patient..

- Influenced by the degree of immunosuppression.
- Symptoms are **less specific** in the **profoundly** more immunosuppressed.
- The speed of onset tends to be **less rapid** in patients with opportunistic organisms such as *Pneumocystis jirovecii* and mycobacterial infections than with bacterial infections
- Typically include fever, cough and breathlessness.
- In *P. jirovecii* pneumonia, symptoms of cough and breathlessness can be present for several days or weeks before the onset of systemic symptoms or the appearance of X-ray abnormalities.

Diagnosis

of Pneumonia in the immunocompromised patient...

- **The approach is informed by the clinical context and severity of the illness.**
- **Invasive investigations**, such as bronchoscopy, BAL, transbronchial biopsy or surgical lung biopsy, are often **impractical**, as many patients are too ill to undergo these **safely**.
- **'Induced sputum'** offers a relatively safe method of obtaining **microbiological samples**

Diagnosis of Pneumonia in the immunocompromised patient..

HRCT is useful in differentiating the likely cause:

- **Focal unilateral airspace opacification favours bacterial infection, mycobacteria or *Nocardia*.**
- **Bilateral opacification favours. *P. jirovecii* pneumonia, fungi, viruses and unusual bacteria, e.g. *Nocardia*.**
- **Cavitation may be seen with *N. asteroides*, mycobacteria and fungi.**
- **The presence of a 'halo sign' may suggest *Aspergillus*.**
- **Pleural effusions suggest a pyogenic bacterial infection and are uncommon in *P. jirovecii* pneumonia.**

Diagnosis

of Pneumonia in the immunocompromised patient...

- **In theory, treatment should be based on the identified causative organism but in practice, this is frequently unknown and broad-spectrum antibiotic therapy is required, such as**
 - **a third-generation cephalosporin or**
 - **A quinolone, plus an antistaphylococcal antibiotic, or**
 - **an antipseudomonal penicillin plus an aminoglycoside.**

Management of Pneumonia in the immunocompromised patient...

- Thereafter, **treatment may be tailored according to the results of investigations and the clinical response.**
- These may dictate the **addition of antifungal or antiviral therapies.**

Thank you

The image shows a hand-drawn illustration on a white card. The central text reads "Thank you" in a vibrant green, cursive script. The word "Thank" is on the top line, and "you" is on the bottom line. The text is surrounded by intricate black ink drawings. A large, flowing vine-like line starts from the bottom left, loops around the word "Thank", and extends towards the right. Various leaves and sprigs are scattered around the text, including a large leaf on the right side and several smaller sprigs at the top and bottom. The entire composition is set against a plain white background, which is placed on a light brown, textured surface.